Cosmo Pharmaceuticals N.V. (0RGI.L)
CHF 59.0
(-1.5%)
CHF 59.0
(-1.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 553.98 Million EUR | -27.07% |
| 2022 | 759.59 Million EUR | -5.71% |
| 2021 | 805.56 Million EUR | 35.12% |
| 2020 | 596.16 Million EUR | 1.88% |
| 2019 | 585.16 Million EUR | -6.48% |
| 2018 | 625.68 Million EUR | 25.65% |
| 2017 | 497.97 Million EUR | 12.29% |
| 2016 | 443.47 Million EUR | 1.26% |
| 2015 | 437.94 Million EUR | 94.11% |
| 2014 | 225.62 Million EUR | -7.15% |
| 2013 | 243 Million EUR | 60.03% |
| 2012 | 151.84 Million EUR | 94.58% |
| 2011 | 78.03 Million EUR | -15.01% |
| 2010 | 91.82 Million EUR | 28.49% |
| 2009 | 71.46 Million EUR | 23.72% |
| 2008 | 57.76 Million EUR | 22.31% |
| 2007 | 47.22 Million EUR | 100.03% |
| 2006 | 23.61 Million EUR | -16.31% |
| 2005 | 28.21 Million EUR | 20.24% |
| 2004 | 23.46 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 638.25 Million EUR | 15.21% |
| 2024 Q2 | 638.25 Million EUR | 0.0% |
| 2023 Q4 | 553.98 Million EUR | 0.0% |
| 2023 Q1 | 736.81 Million EUR | -3.0% |
| 2023 Q2 | 736.81 Million EUR | 0.0% |
| 2023 FY | 553.98 Million EUR | -27.07% |
| 2023 Q3 | 553.98 Million EUR | -24.81% |
| 2022 FY | 759.59 Million EUR | -5.71% |
| 2022 Q4 | 759.59 Million EUR | 0.0% |
| 2022 Q2 | 765.25 Million EUR | 0.0% |
| 2022 Q1 | 765.25 Million EUR | -5.0% |
| 2022 Q3 | 759.59 Million EUR | -0.74% |
| 2021 Q2 | 562.75 Million EUR | 0.0% |
| 2021 FY | 805.56 Million EUR | 35.12% |
| 2021 Q3 | 805.56 Million EUR | 43.15% |
| 2021 Q1 | 562.75 Million EUR | -5.6% |
| 2021 Q4 | 805.56 Million EUR | 0.0% |
| 2020 Q4 | 596.16 Million EUR | 0.0% |
| 2020 Q2 | 596.61 Million EUR | 0.0% |
| 2020 FY | 596.16 Million EUR | 1.88% |
| 2020 Q1 | 596.61 Million EUR | 1.96% |
| 2020 Q3 | 596.16 Million EUR | -0.08% |
| 2019 Q3 | 585.16 Million EUR | -1.61% |
| 2019 Q1 | 594.73 Million EUR | -4.95% |
| 2019 Q2 | 594.73 Million EUR | 0.0% |
| 2019 FY | 585.16 Million EUR | -6.48% |
| 2019 Q4 | 585.16 Million EUR | 0.0% |
| 2018 Q1 | 479.58 Million EUR | -3.69% |
| 2018 FY | 625.68 Million EUR | 25.65% |
| 2018 Q4 | 625.68 Million EUR | 0.0% |
| 2018 Q3 | 625.68 Million EUR | 30.46% |
| 2018 Q2 | 479.58 Million EUR | 0.0% |
| 2017 Q4 | 497.97 Million EUR | 0.0% |
| 2017 FY | 497.97 Million EUR | 12.29% |
| 2017 Q1 | 507.26 Million EUR | 14.38% |
| 2017 Q2 | 507.26 Million EUR | 0.0% |
| 2017 Q3 | 497.97 Million EUR | -1.83% |
| 2016 Q2 | 452.61 Million EUR | 0.0% |
| 2016 FY | 443.47 Million EUR | 1.26% |
| 2016 Q1 | 452.61 Million EUR | 3.35% |
| 2016 Q3 | 443.47 Million EUR | -2.02% |
| 2016 Q4 | 443.47 Million EUR | 0.0% |
| 2015 Q4 | 437.94 Million EUR | 0.0% |
| 2015 Q3 | 437.94 Million EUR | -2.78% |
| 2015 FY | 437.94 Million EUR | 94.11% |
| 2015 Q2 | 450.47 Million EUR | 0.0% |
| 2015 Q1 | 450.47 Million EUR | 99.66% |
| 2014 Q4 | 225.62 Million EUR | 0.0% |
| 2014 Q2 | 199.01 Million EUR | 0.0% |
| 2014 Q1 | 199.01 Million EUR | -18.1% |
| 2014 FY | 225.62 Million EUR | -7.15% |
| 2014 Q3 | 225.62 Million EUR | 13.37% |
| 2013 Q1 | 207.33 Million EUR | 36.55% |
| 2013 FY | 243 Million EUR | 60.03% |
| 2013 Q4 | 243 Million EUR | 0.0% |
| 2013 Q3 | 243 Million EUR | 17.2% |
| 2013 Q2 | 207.33 Million EUR | 0.0% |
| 2012 Q4 | 151.84 Million EUR | 0.0% |
| 2012 FY | 151.84 Million EUR | 94.58% |
| 2012 Q2 | 123.78 Million EUR | 0.0% |
| 2012 Q3 | 151.84 Million EUR | 22.67% |
| 2011 Q2 | 91.68 Million EUR | 0.0% |
| 2011 Q4 | 78.03 Million EUR | 0.0% |
| 2011 FY | 78.03 Million EUR | -15.01% |
| 2010 Q2 | 92.46 Million EUR | 0.0% |
| 2010 Q4 | 91.82 Million EUR | 0.0% |
| 2010 FY | 91.82 Million EUR | 28.49% |
| 2009 Q4 | 71.46 Million EUR | 0.0% |
| 2009 FY | 71.46 Million EUR | 23.72% |
| 2008 FY | 57.76 Million EUR | 22.31% |
| 2007 FY | 47.22 Million EUR | 100.03% |
| 2006 FY | 23.61 Million EUR | -16.31% |
| 2005 FY | 28.21 Million EUR | 20.24% |
| 2004 FY | 23.46 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 76.39 Million CHF | -625.2% |
| Tecan Group AG | 2.07 Billion CHF | 73.289% |
| Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | -405.322% |
| Basilea Pharmaceutica AG | 173.28 Million CHF | -219.686% |
| Bachem Holding AG | 1.68 Billion CHF | 67.081% |
| Siegfried Holding AG | 1.86 Billion CHF | 70.24% |
| Molecular Partners AG | 198.35 Million CHF | -179.291% |